✦ LIBER ✦

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study

✍ Scribed by Martin Hjorth; Øyvind Hjertner; Lene Meldgaard Knudsen; Nina Gulbrandsen; Erik Holmberg; Per Trøllund Pedersen; Niels Frost Andersen; Björn Andréasson; Rolf Billström; Kristina Carlson; Margaretha S. Carlsson; Max Flogegård; Karin Forsberg; Peter Gimsing; Torbjörn Karlsson; Olle Linder; Hareth Nahi; Annika Othzén; Agneta Swedin; for the Nordic Myeloma Study Group (NMSG)

Book ID: 114795694
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 357 KB
Volume: 88
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.2012.01775.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral Melphalan, Dexamethasone, and Thali

Oral Melphalan, Dexamethasone, and Thalidomide for the Treatment of Refractory Multiple Myeloma

✍ Norio Asou; Yoshiharu Izuno; Toshiya Okubo; Kazuhiko Ide; Hiroshi Ueno; Makoto K 📂 Article 📅 2007 🏛 Carden Jennings Publishing 🌐 English ⚖ 58 KB

Use of melphalan, thalidomide, and dexam

Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma

✍ Gordan Srkalovic; Paul Elson; Beth Trebisky; Mary Ann Karam; Mohamad A. Hussein 📂 Article 📅 2002 🏛 Springer US 🌐 English ⚖ 88 KB

Thalidomide–dexamethasone plus pegylated

Thalidomide–dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide–dexamethasone: a case-matched study in advanced multiple myeloma

✍ Massimo Offidani; Sara Bringhen; Laura Corvatta; Patrizia Falco; Monica Marconi; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 492 KB

Bortezomib in combination with thalidomi

Bortezomib in combination with thalidomide and dexamethasone—a successful treatment regimen in refractory extramedullary multiple myeloma

✍ Dominik Dytfeld; Magdalena Matuszak; Krzysztof Lewandowski; Mieczysław Komarnick 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 84 KB

Bortezomib, low-dose intravenous melphal

Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma

✍ Rakesh Popat; Heather Oakervee; Catherine Williams; Mark Cook; Charles Craddock; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB

Bortezomib, thalidomide, and dexamethaso

Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma : A retrospective study

✍ Jonathan L. Kaufman; Ajay Nooka; Mark Vrana; Charise Gleason; L. Thompson Heffne 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

## Abstract ## BACKGROUND: This single‐center retrospective study determined the efficacy of bortezomib, thalidomide, and dexamethasone (BTD) as induction for patients with multiple myeloma (MM) who were eligible for autologous stem cell transplantation (ASCT). ## METHODS: Patients with symptoma